Det lå blandt andet bag Novos beslutning om sidste år at investere omkring 80 milliarder kroner i tre nye fabrikker – heraf ...
Ritzau on MSN2d
Novo Nordisk er ikke immun over for Trumps toldtruslerNovo Nordisk ser sig selv stå et godt sted over for højere amerikansk told, men selskabet er ikke immunt. Den danske ...
Fabrikker og fedmemedicin udløser stigende klimaregning til NovoOnsdag morgen kunne Novo Nordisk fremvise et pænt årsregnskab ...
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Vækst fik Novos CO2-udledning til at vokse med 23 procent i 2024. Alligevel holder selskabet fast i klimamål. CO2-udledningen ...
The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...
Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...
Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback